Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
出版年份 2016 全文链接
标题
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
作者
关键词
Dogs, B cells, Lymphomas, Lymph nodes, Lymphoma cells, Toxicity, Adverse events, Cancer treatment
出版物
PLoS One
Volume 11, Issue 7, Pages e0159607
出版商
Public Library of Science (PLoS)
发表日期
2016-07-20
DOI
10.1371/journal.pone.0159607
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients
- (2015) Todd Covey et al. CANCER RESEARCH
- BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia
- (2015) S-S Chen et al. LEUKEMIA
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
- (2014) H. E. Kohrt et al. BLOOD
- Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
- (2014) Xiaohui Zheng et al. Cancer Cell International
- Phase II Evaluation of VDC-1101 in Canine Cutaneous T-Cell Lymphoma
- (2014) M.A. Morges et al. JOURNAL OF VETERINARY INTERNAL MEDICINE
- Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study
- (2014) Cheryl A. London et al. PLoS One
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Gene Profiling of Canine B-Cell Lymphoma Reveals Germinal Center and Postgerminal Center Subtypes with Different Survival Times, Modeling Human DLBCL
- (2013) K. L. Richards et al. CANCER RESEARCH
- Modeling Opportunities in Comparative Oncology for Drug Development
- (2013) I. K. Gordon et al. ILAR JOURNAL
- A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi
- (2013) Robbert Hoogeboom et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
- (2013) S Cheng et al. LEUKEMIA
- Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
- (2013) Munevver Cinar et al. LEUKEMIA RESEARCH
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Gene Expression Profiling Identifies Common Molecular Signatures of NF-κB Activation in Canine and Human Diffuse Large B Cell Lymphoma (DLBCL)
- (2013) Manikhandan A. V. Mudaliar et al. PLoS One
- B cell receptor signaling in chronic lymphocytic leukemia
- (2013) Jan A. Burger et al. TRENDS IN IMMUNOLOGY
- Self-antigen recognition by follicular lymphoma B-cell receptors
- (2012) K. L. Sachen et al. BLOOD
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Profiling Reveals Prognostically Significant Subtypes of Canine Lymphoma
- (2012) A. M. Frantz et al. VETERINARY PATHOLOGY
- Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
- (2011) A. Hadzidimitriou et al. BLOOD
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
- (2011) Cheryl A. London et al. PLoS One
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma
- (2010) Barbara C. Rütgen et al. LEUKEMIA RESEARCH
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- (2009) Mara Compagno et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now